Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cordycepin is a purine nucleoside antimetabolite and antibiotic originally isolated from the fungus *Cordyceps militaris*. Also known as 3’-deoxyadenosine, it is structurally similar to adenosine but lacks a hydroxyl group at the 3' position of its ribose moiety. Cordycepin exhibits a broad spectrum of biological activities, including antitumor, antioxidant, anti-inflammatory, immunomodulatory, antiviral, and metabolic regulatory effects[1][4][5]. Its mechanism of action involves inhibition of RNA synthesis by acting as an adenosine analog and incorporation into RNA chains; this leads to premature termination of transcription[4][5]. Additionally, cordycepin acts as a pro-drug that activates AMP-activated protein kinase (AMPK) after being metabolized intracellularly into cordycepin monophosphate[6]. This activation influences cellular energy metabolism and has been linked to beneficial effects in cancer cell apoptosis (via mitochondrial pathways), metabolic disorders such as diabetes and hyperlipidemia, immune modulation (including both immunostimulatory and immunosuppressive actions), and potential use in autoimmune diseases or transplant rejection management[1][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cordycepin.